Cardiovascular Today—October 23, 2025

Get the latest on Cardiovascular this week, including key industry developments, pipeline updates, and biopharma progress.

In Today’s Newsletter

💵 Jupiter Endovascular raises $40M for TFX platform [1] [US; 08 Oct 2025]

https://www.cardiovascularnews.com/jupiter-endovascular-secures-funds-to-continue-development-of-tfx-platform/
Key point: Vertex pulmonary embolectomy system (SPIRARE) progressing to pivotal trial.
Context: Series B funding closes for TFX technology to support SPIRARE II trial and commercialization.
Implication: Potential to reshape endovascular treatment with more stable catheter interventions.

❤️ Milestone Pharmaceuticals to present etripamil data at AHA 2025 [2] [US; 09 Oct 2025]

https://investors.milestonepharma.com/news-releases/news-release-details/milestoner-pharmaceuticals-present-data-etripamil-american-heart
Key point: Self-administered etripamil’s efficacy, safety, and tolerability in PSVT discussed.
Context: Poster on etripamil for PSVT presented at AHA.
Implication: Clinician and patient interest in novel PSVT treatments.

🔄 ESC 2025 updates TAVI guidelines [3] [EU; 09 Oct 2025]

https://www.emjreviews.com/cardiology/congress-review/congress-feature-esc-congress-update-on-esc-eacts-2025-valvular-heart-disease-guidelines/
Key point: Reduced TAVI age threshold from 75 to 70 years; changes in regurgitation management.
Context: ESC and EACTS release updated guidelines on aortic stenosis and regurgitation treatments.
Implication: More patients eligible for TAVI; impacts clinical decision-making and patient care.

🧠 Methinks secures second FDA clearance for CTA Stroke solution [4] [US; 09 Oct 2025]

https://neuronewsinternational.com/methinks-expands-stroke-detection-solution-into-contrast-imaging-with-second-us-fda-clearance/
Key point: High sensitivity and specificity for detecting LVOs, including distal occlusions.
Context: Methinks granted FDA clearance for CTA-based stroke detection tool.
Implication: Streamlining stroke triage and care in diverse healthcare settings.

🧸 Abbott unveils “Abbey Bear” to teach LVAD therapy to kids [5] [EU; 09 Oct 2025]

https://cardiovascularnews.com/abbey-bear-seeks-to-demystify-lvad-treatment-for-young-heart-failure-patients/
Key point: Plush bear with LVAD parts to help children understand their heart device.
Context: New educational tool launched for LVAD awareness in children.
Implication: Easier conversations with pediatric patients and families, enhancing emotional and psychological support.

🏥 Dapagliflozin shows no quality-of-life benefit post-TAVI [6] [EU; 10 Oct 2025]

https://cardiovascularnews.com/dapagliflozin-does-not-add-to-quality-of-life-benefit-gained-from-tavi/
Key point: Dapagliflozin reduces death and heart failure but does not improve KCCQ scores post-TAVI.
Context: DapaTAVI trial finds no added quality-of-life benefits for patients after TAVI.
Implication: Reaffirms dapagliflozin’s role in clinical event reduction but not symptom enhancement post-TAVI.

🧠 TO_AITION project bridges gap between cardiovascular and mental health [7] [EU; 13 Oct 2025]

https://www.escardio.org/The-ESC/Press-Office/Press-releases/to_aition-project-uncovers-links-between-cardiovascular-disease-and-mental-healt
Key point: Cloud-based platform for joint cardiovascular and mental health care rolled out.
Context: EU-funded TO_AITION project explores links between cardiovascular disease and depression.
Implication: Advances in integrated care for CVD and mental health comorbidities.

💊 Vasa Therapeutics receives FDA IND clearance for VS-041 in HFpEF [8] [US; 13 Oct 2025]

https://firstwordpharma.com/story/6320981
Key point: Phase 1c trial in HFpEF patients with elevated endotrophin set to begin.
Context: IND clearance for VS-041 to treat heart failure with preserved ejection fraction (HFpEF).
Implication: Potential breakthrough in disease-modifying treatments for HFpEF.

🫀 EACTS 2025 presents new data on aortic arch remodelling device [9] [EU; 14 Oct 2025]

https://cardiovascularnews.com/eacts-2025-hears-new-data-on-aortic-arch-remodelling-device/
Key point: Positive results in patients with visceral and renal malperfusion treated with the Ascyrus medical dissection stent.
Context: Artivion presents data from AMDS PERSEVERE and PROTECT trials.
Implication: Encouraging outcomes for complex aortic dissections, expanding device options for high-risk patients.

🏥 Medtronic’s Endurant receives FDA labelling approval for rAAA treatment [10] [US; 14 Oct 2025]

https://cardiovascularnews.com/medtronics-endurant-receives-us-fda-labelling-approval-to-remove-raaa-treatment-warning/
Key point: First FDA-approved label to remove treatment warning, enhancing physician confidence.
Context: Medtronic’s Endurant stent graft system now approved for rAAA treatment.
Implication: Supports broader use of Endurant for ruptured abdominal aortic aneurysms (rAAA).

Why it matters

Funding and clinical progress in cardiovascular technologies are increasing, from endovascular innovations [1] to heart failure therapies [8].
Integration of AI in stroke detection [4] and expanded LVAD understanding for pediatric patients [5] improves treatment outcomes and patient engagement.
TAVI and valvular disease guideline updates reflect growing evidence for more inclusive treatment options [3], especially for younger patients.
The TO_AITION project advances interdisciplinary approaches linking heart and mental health conditions, offering tools to improve patient care [7].

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

FAQ

What does Jupiter’s Series B financing mean for TFX?

The funding will be used to advance the TFX platform and ongoing clinical trials (SPIRARE I and II), with FDA-cleared Vertex catheter and upcoming pivotal trial data [1].

How significant is the new data from Milestone Pharmaceuticals?

Milestone’s upcoming AHA presentation on etripamil in PSVT aims to strengthen the case for its self-administered treatment for rapid heart rhythm episodes [2].

Why is the dapagliflozin trial important post-TAVI?

Dapagliflozin showed no improvement in quality of life post-TAVI, although it reduced clinical events, which helps define its role in patient care after valve replacement [6].

What’s the future of heart failure therapies with VS-041?

Vasa’s small molecule inhibitor of matrix metalloproteinases, VS-041, shows promise for treating HFpEF, with a new Phase 1c trial targeting endotrophin levels [8].

Entities / Keywords

Jupiter Endovascular; TFX platform; SPIRARE II; Vertex catheter; Milestone Pharmaceuticals; etripamil; PSVT; AHA 2025; ESC/EACTS 2025; TAVI; aortic valve guidelines; Methinks; CTA Stroke; stroke detection; FDA 510(k) clearance; Abbott; LVAD; Abbey Bear; HeartMate 3; Dapagliflozin; TAVI; DapaTAVI trial; quality of life; TO_AITION; cardiovascular disease; mental health; depression; Vasa Therapeutics; VS-041; HFpEF; endotrophin; EACTS 2025; Ascyrus medical dissection stent; AMDS; Medtronic; Endurant; rAAA.